<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Seizures and epilepsy in children: Refractory seizures</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Seizures and epilepsy in children: Refractory seizures</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Seizures and epilepsy in children: Refractory seizures</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angus Wilfong, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1539300474"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most children with epilepsy achieve reasonably good seizure control with antiseizure medication therapy, but some are refractory despite numerous medications. Medical treatment failure is often apparent early in the course of treatment. In these cases, referral to a comprehensive epilepsy center is appropriate to explore additional therapeutic options, including epilepsy surgery, vagus nerve stimulation, and the ketogenic diet.</p><p>There is no standardized definition of medically intractable epilepsy. A task force of the International League Against Epilepsy proposed that drug-resistant epilepsy be defined as failure of adequate trials of two tolerated and appropriately chosen and used antiseizure medication schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom [<a href="#rid1">1</a>].</p><p>This topic discusses the management of seizures and epilepsy in children who are not controlled with initial antiseizure medication therapy. The clinical features, diagnosis, and initial management of seizures and epilepsy in children are presented separately:</p><p> <a class="medical medical_review" href="/z/d/html/6199.html" rel="external">Seizures and epilepsy in children: Classification, etiology, and clinical features</a><br/> <a class="medical medical_review" href="/z/d/html/6218.html" rel="external">Seizures and epilepsy in children: Clinical and laboratory diagnosis</a><br/> <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">Seizures and epilepsy in children: Initial treatment and monitoring</a><br/> <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">Epilepsy syndromes in children</a><br/> <a class="medical medical_review" href="/z/d/html/129781.html" rel="external">Epilepsy in children: Comorbidities, complications, and outcomes</a></p><p class="headingAnchor" id="H1539304708"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>When seizures do not respond as expected to initial antiseizure medication therapy, it is important to reconsider the seizure classification and the appropriateness of the antiseizure medication regimens that have been tried. In addition, clinicians should consider whether the diagnosis of epilepsy is accurate, as misdiagnosis is common. Common mimics of seizures include psychogenic nonepileptic seizures and other nonepileptic paroxysmal disorders  (<a class="graphic graphic_table graphicRef81289" href="/z/d/graphic/81289.html" rel="external">table 1</a>).</p><p>Additional reasons for apparent treatment failure that do not reflect true intractability include:</p><p class="bulletIndent1"><span class="glyph">●</span>An incorrect diagnosis or seizure classification (ie, focal versus generalized), leading to an inappropriate antiseizure medication choice that might be aggravating seizures  (<a class="graphic graphic_table graphicRef78021" href="/z/d/graphic/78021.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring", section on 'Seizure-related considerations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inappropriate antiseizure medication dosing (either too high or too low) or frequency. (See  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring", section on 'Drug administration and dosing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonadherence to antiseizure medication therapy. (See  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring", section on 'Adherence to antiseizure medications'</a>.)</p><p></p><p class="headingAnchor" id="H1539304715"><span class="h1">MEDICAL THERAPY</span><span class="headingEndMark"> — </span>Children who fail to respond to antiseizure medication monotherapy at adequate doses or do not tolerate effective doses should be started on a second antiseizure medication, although the likelihood of complete seizure remission decreases with each subsequent failed antiseizure medication trial. The likelihood of success varies based on the underlying etiology.</p><p class="headingAnchor" id="H1539301689"><span class="h2">Adding a second antiseizure medication</span><span class="headingEndMark"> — </span>The first antiseizure medication fails in 20 to 40 percent of children with epilepsy; lack of efficacy and side effects contribute roughly equally to treatment failure [<a href="#rid2">2</a>]. Adding a second antiseizure medication is a reasonable next step when seizures are resistant to adequate doses of the initial drug.</p><p class="bulletIndent1"><span class="glyph">●</span>If the initial drug was partially effective, it should be continued until reasonable levels of the new antiseizure medication are achieved. Tapering the first drug can then be attempted if seizures are controlled.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the initial antiseizure medication is ineffective, it can be tapered earlier, as the dose of the second drug is increased. The pharmacokinetics of either drug can be altered by the other; serum levels may have to be monitored closely.</p><p></p><p>A second antiseizure medication may also be considered in children with several different seizure types when monotherapy is not effective. In one practice, the clinicians found that children with status epilepticus, developmental disabilities, and multiple seizure types were more likely to require polytherapy than those without these features [<a href="#rid3">3</a>].</p><p>Virtually every combination of antiseizure medications has been used. Certain combinations should be avoided when mechanisms of action overlap and toxicities are additive, such as any combinations of <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>, <a class="drug drug_pediatric" data-topicid="12727" href="/z/d/drug information/12727.html" rel="external">primidone</a>, and benzodiazepines, all of which are central nervous system depressants. <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">Phenytoin</a> and <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a> also have overlapping mechanisms of action and are usually not given together. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p>There are instances in which the synergistic interaction of two antiseizure medications improves seizure control. Children with certain generalized epilepsy syndromes occasionally require a combination of <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproate</a> and <a class="drug drug_pediatric" data-topicid="13288" href="/z/d/drug information/13288.html" rel="external">ethosuximide</a> or <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">lamotrigine</a>. (See  <a class="medical medical_review" href="/z/d/html/14450.html" rel="external">"Childhood absence epilepsy", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/17192.html" rel="external">"Juvenile myoclonic epilepsy", section on 'Adjunctive therapy'</a>.)</p><p class="headingAnchor" id="H1539301745"><span class="h2">Inadequate response to multidrug therapy</span><span class="headingEndMark"> — </span>There are numerous reasons why seizure control may be inadequate despite multidrug therapy, and in some cases seizure frequency is improved when the number of antiseizure medications is reduced:</p><p class="bulletIndent1"><span class="glyph">●</span>In many cases, a second antiseizure medication was added to an initial, ineffective antiseizure medication that was not then discontinued. If the seizures increased, a third medication often was added. The first or second antiseizure medication may actually have increased the seizure frequency, and the problem was compounded further with the addition of more antiseizure medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most of the antiseizure medications have been reported to increase seizure frequency in a small percentage of patients and, in some instances, induce new seizure types [<a href="#rid4">4</a>]. These seizures may occur at low or therapeutic doses of some medications and at toxic doses in others. <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">Carbamazepine</a>, for example, can precipitate atonic seizures, particularly in children with Lennox-Gastaut syndrome. <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">Phenytoin</a> can worsen absence seizures at therapeutic doses and cause generalized seizures at toxic doses.</p><p></p><p>Thus, the initial approach to the child with intractable seizures on polytherapy is to slowly decrease the antiseizure medication that has been the least effective.</p><p>When a child has intractable epilepsy despite treatment with more than one antiseizure medication, it is also reasonable to reevaluate the diagnosis of epilepsy and initiate referral to a comprehensive epilepsy center to determine eligibility for epilepsy surgery and other treatment modalities, such as dietary therapy and vagus nerve stimulation [<a href="#rid5">5</a>]. (See <a class="local">'Epilepsy surgery'</a> below and <a class="local">'Vagus nerve stimulation'</a> below and <a class="local">'The ketogenic diet'</a> below.)</p><p class="headingAnchor" id="H1539301819"><span class="h2">Home rescue therapy (transmucosal antiseizure medications)</span><span class="headingEndMark"> — </span>Parents and caregivers of children with frequent, prolonged seizures are often provided with transmucosal benzodiazepines for home rescue therapy in an attempt to overcome delays in treatment related to emergency transportation and provision of intravenous access. Such problems have led to increased use of transmucosal routes of antiseizure medication delivery, such as rectal, buccal, intranasal, and sublingual administration, that allow for earlier initiation of rescue therapy in the home or prehospital setting [<a href="#rid6">6</a>].</p><p>The largest experience is with rectal <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a>, although accumulating evidence suggests that buccal <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> is also safe and may be more effective than rectal diazepam [<a href="#rid6">6-8</a>]. Intramuscular and intranasal administration of midazolam appears to have similar efficacy as rectal diazepam. Transmucosal administration of midazolam will likely become first-line therapy for out-of-hospital emergency therapy once a convenient formulation for nonmedical personnel is approved and available. (See <a class="local">'Rectal therapy'</a> below and <a class="local">'Buccal therapy'</a> below.)</p><p>Prolonged seizures that do not respond to transmucosal therapy require hospitalization, intravenous administration of antiseizure medications, and may require intensive care unit management. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>.)</p><p class="headingAnchor" id="H1539301915"><span class="h3">Rectal therapy</span><span class="headingEndMark"> — </span>Rectal benzodiazepines are an effective and relatively safe emergency treatment, particularly for patients who live at some distance from a medical facility, those requiring emergency therapy while traveling, and those whose seizures occur in clusters.</p><p><a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">Diazepam</a> is available in a rectal gel (Diastat) that is obtained from the pharmacy in prefilled ready-to-use syringes that are set to deliver a specific dose. These have a long shelf life (years) and do not require refrigeration. The rates of absorption and response are slower than those of intravenous diazepam but faster than with oral administration. Respiratory depression is extremely rare [<a href="#rid9">9</a>], although if concerns about this possible complication exist, particularly in a handicapped child, a test dose can be given under physician supervision.</p><p>Rectal <a class="drug drug_general" data-topicid="83875" href="/z/d/drug information/83875.html" rel="external">paraldehyde</a> may also be used in the setting of a prolonged convulsion when other routes of antiseizure medication administration are not available. It is administered as a dose of 0.8 mL/kg of a 0.4 mL/kg liquid mixed 1:1 with olive oil. In a case series of 53 episodes of prolonged convulsions in 30 patients, rectal paraldehyde terminated the convulsion in 62 percent [<a href="#rid10">10</a>]. There was no respiratory depression or other adverse events recorded. Paraldehyde is not available in the United States.</p><p>Many antiseizure medications can be given as a rectal suppository for short periods (eg, postoperatively) and occasionally as chronic treatment for patients unable to take oral medications. Any antiseizure medication available as an oral suspension (<a class="drug drug_pediatric" data-topicid="13170" href="/z/d/drug information/13170.html" rel="external">clonazepam</a>, <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a>, <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproate</a>, <a class="drug drug_pediatric" data-topicid="12664" href="/z/d/drug information/12664.html" rel="external">oxcarbazepine</a>, <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">levetiracetam</a>) can be given rectally for short periods. Carbamazepine has a significant cathartic effect.</p><p class="headingAnchor" id="H1539301974"><span class="h3">Buccal therapy</span><span class="headingEndMark"> — </span>Buccal <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> therapy uses the intravenous formulation of midazolam hydrochloride delivered into the buccal cavity between the gum and cheek [<a href="#rid7">7</a>]. Buccal midazolam is approved for treatment of acute seizures in children in the United Kingdom and the European Union but is not yet approved in the United States. The suggested doses are 2.5 mg for infants between 6 months and 1 year, 5 mg for those aged 1 to &lt;5 years, 7.5 mg for those aged 5 to &lt;10 years, and 10 mg for those age 10 to &lt;18 years [<a href="#rid6">6</a>].</p><p>Buccal <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> is effective for the emergency treatment of seizures in children, as demonstrated by at least three randomized clinical trials [<a href="#rid11">11,12</a>]. In the earlier and smaller trial that evaluated 79 seizures in 28 children with severe epilepsy, buccal midazolam was as effective as rectal <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a> at stopping seizures [<a href="#rid11">11</a>].</p><p>A subsequent multicenter randomized controlled trial evaluated 219 seizures in 177 children ages six months and older (median age three years) with new-onset seizures or existing epilepsy who presented to the emergency department with ongoing seizures and no established intravenous access [<a href="#rid12">12</a>]. Buccal <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> was more effective than rectal <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a> for either stopping seizure activity within 10 minutes without respiratory depression or preventing another seizure within one hour (56 versus 27 percent, respectively). The risk of respiratory depression with buccal midazolam was low and similar to the risk with rectal diazepam. The dose of buccal midazolam used was 2.5 mg, 5 mg, 7.5 mg, and 10 mg for children ages 6 to 12 months, 1 to 4 years, 5 to 9 years, and 10 or more years, respectively.</p><p>A randomized trial compared buccal <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> with intravenous <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a> in 120 children presenting to an emergency department with convulsive seizures [<a href="#rid13">13</a>]. Time to treatment was shorter with buccal midazolam; time from administration to seizure control was shorter with diazepam. Overall, there was a shorter time from treatment decision to control of seizures for buccal therapy.</p><p class="headingAnchor" id="H1539302105"><span class="h3">Intranasal therapy</span><span class="headingEndMark"> — </span>A nasal spray formulation of <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a> is available; it is approved by the US Food and Drug Administration (FDA) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) in patients age 6 years and older [<a href="#rid14">14</a>].</p><p>Nasal <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">midazolam</a> is also approved by the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) in patients age 12 years and older [<a href="#rid15">15</a>]. A 2021 systematic review and meta-analysis of 10 studies comparing intranasal midazolam (n = 169) versus intravenous or rectal benzodiazepines (n = 161) for the treatment of acute seizures found no significant difference between the two treatment groups for time to seizure cessation or control of seizures [<a href="#rid16">16</a>].</p><p>Intranasal <a class="drug drug_pediatric" data-topicid="12565" href="/z/d/drug information/12565.html" rel="external">lorazepam</a> also appears to be an effective treatment option [<a href="#rid17">17</a>], and in one study appeared to have similar efficacy to intravenous lorazepam [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1208769302"><span class="h2">School action plans</span><span class="headingEndMark"> — </span>A school action plan should be in place for children with frequent, prolonged seizures who use rescue therapy in the home environment, with specific instructions for medical and nonmedical school personnel [<a href="#rid19">19,20</a>]. The American Academy of Pediatrics has published a guideline highlighting practical and legal considerations for clinicians, families, guardians, caregivers, and schools when developing school-based plans [<a href="#rid21">21</a>]. In addition to parameters about when a rescue medication should be given, tailored to the child's individual history, plans should also generally include discussion of potential adverse effects, guidance about the types of situations in which personnel should seek further medical assistance, and discussion of when a child is safe to remain in school after a seizure.</p><p class="headingAnchor" id="H1539302193"><span class="h1">EPILEPSY SURGERY</span><span class="headingEndMark"> — </span>Surgical interventions should be considered, regardless of age, in children who have persistent, frequent seizures that are having an adverse impact upon their lives or are interfering with their cognitive and psychosocial development [<a href="#rid22">22,23</a>]. The type of surgery that a child may be eligible for is individualized based on a comprehensive epilepsy evaluation.</p><p class="headingAnchor" id="H1539304774"><span class="h2">Surgical evaluation</span><span class="headingEndMark"> — </span>Eligibility for epilepsy surgery is determined by a comprehensive evaluation that includes efforts to identify the epileptogenic zone and a determination of the extent to which it can be resected safely. Components of the evaluation include a clinical evaluation, neuropsychologic testing, routine and video electroencephalography (EEG), high-resolution magnetic resonance imaging (MRI), and other advanced imaging techniques. Components of the surgical evaluation of epilepsy are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">"Surgical treatment of epilepsy in adults", section on 'Surgical evaluation'</a>.)</p><p class="headingAnchor" id="H1539304780"><span class="h2">Specific procedures</span><span class="headingEndMark"> — </span>Surgical approaches can be divided into relatively less invasive procedures, such as vagus nerve stimulation, and surgeries such as focal resections, lobar or multilobar resections, corpus callosotomy [<a href="#rid24">24</a>], hemispherectomy, and multiple subpial transection [<a href="#rid25">25</a>].</p><p>The procedure selected depends upon the type and localization of the seizures. Children with a well-localized epileptic focus, particularly if a lesion is present on imaging studies in the same location, do very well with removal of the abnormal tissue (lesionectomy). Children with uni-hemispheric syndromes such as hemimegalencephaly [<a href="#rid26">26,27</a>], Sturge-Weber syndrome, or Rasmussen disease [<a href="#rid28">28,29</a>] can be candidates for removal (hemispherectomy) or undercutting of the cortex of an entire hemisphere (functional hemispherectomy). An individualized approach is taken for complex lesions such as polymicrogyria, in which the epileptic zone may only partially overlap with the structural abnormality [<a href="#rid30">30,31</a>].</p><p>When patients are appropriately selected for epilepsy surgery after comprehensive surgical evaluation, observational studies and a single randomized trial in children find that seizure outcomes are superior to those achieved with continued medical therapy alone [<a href="#rid32">32,33</a>]. Improvements in seizure frequency are generally highest after medial temporal lobectomy or extratemporal lesional surgeries, intermediate after hemispherectomy, and lowest after corpus callosotomy. The risk of new or worsened neurologic deficits such as hemiparesis varies by specific procedure and preoperative neurologic baseline and is generally highest with hemispherectomy and extratemporal resections and lowest with medial temporal lobectomy.</p><p>In the only randomized trial of epilepsy surgery in children to date, one-year seizure freedom rates after surgery and appropriate medical therapy were superior to wait-list control and medical therapy alone for the entire cohort (77 versus 7 percent; n = 116) and varied according to the performed or planned procedure [<a href="#rid32">32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Temporal lobectomy (n = 29) – 100 versus 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Extratemporal resection (n = 31) – 92 versus 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hemispherectomy (n = 23) – 87 versus 0 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Corpus callosotomy (n = 26) – 0 versus 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypothalamic hamartoma resection/disconnection (n = 7) – 100 versus 0 percent</p><p></p><p>Clinicians, patients, and parents were necessarily unblinded. Nearly all secondary outcomes improved in the surgical group at one year compared with the presurgical baseline, including scores on scales of seizure severity, quality of life, social maturity, and child behavior. Hemiparesis was the most common severe adverse event and occurred exclusively in the hemispherectomy group (26 percent); all but two patients recovered to antigravity strength or better by 12 months.</p><p class="headingAnchor" id="H1539302358"><span class="h3">Temporal lobectomy</span><span class="headingEndMark"> — </span>The most commonly performed invasive surgical procedure for epilepsy is temporal lobectomy as a treatment for focal-onset seizures arising from the medial temporal lobe. Among adults, the most common histopathologic diagnosis in temporal lobectomy specimens is hippocampal sclerosis [<a href="#rid34">34,35</a>]. Among children undergoing epilepsy surgery, hippocampal sclerosis makes up only approximately 15 percent of cases; more commonly, children have cortical malformations or low-grade tumors in temporal or extratemporal locations [<a href="#rid35">35,36</a>]. (See <a class="local">'Extratemporal cortical resection'</a> below.)</p><p>Cohort studies and a single randomized trial suggest that children who undergo temporal lobectomy for mesial temporal lobe epilepsy can achieve similar, if not greater, benefits on seizure control compared with adults, with reported rates of complete seizure freedom ranging from 65 to 100 percent at one to five years after surgery [<a href="#rid32">32,36-39</a>].</p><p class="headingAnchor" id="H1539302448"><span class="h3">Extratemporal cortical resection</span><span class="headingEndMark"> — </span>The results of resective surgery in children with extratemporal foci are similar to those of temporal lobectomy if a discrete lesion is present on preoperative neuroimaging. This appears to be true even if preoperative EEG recording demonstrates bilateral or generalized epileptiform activity [<a href="#rid40">40</a>]. Malformations of cortical development and low-grade primary brain tumors (eg, ganglioglioma, dysembryoplastic neuroepithelial tumor) are the most common causative lesions (both temporal and extratemporal) [<a href="#rid35">35</a>].</p><p>Rates of complete seizure remission range from 80 to 92 percent at one year after extratemporal cortical resection of lesional tissue [<a href="#rid32">32,35,41,42</a>].</p><p>Results in nonlesional cases (MRI-negative) are less gratifying, with success rates reported as less than 40 percent in one series [<a href="#rid43">43</a>]. However, the application of newer technologies in preoperative assessment may modify this somewhat. One study found that surgical success rates similar to those seen with MRI-positive patients were seen in MRI-negative patients in whom the epileptogenic region was identified by combination of ictal single-photon emission computed tomography (SPECT), positron emission tomography (PET), and intracranial EEG monitoring [<a href="#rid44">44</a>].</p><p>The occurrence of early (within two weeks) postoperative seizures was seen in 26 percent of children in one study and identified patients less likely to have a long-term seizure remission [<a href="#rid45">45</a>].</p><p>Cohort studies suggest that individuals with unifocal lesions, particularly low-grade tumors, are more likely to achieve seizure remission than those with no or multifocal lesions and/or cerebral dysplasia [<a href="#rid35">35,38,39</a>].</p><p class="headingAnchor" id="H1539302550"><span class="h3">Hemispherectomy</span><span class="headingEndMark"> — </span>Hemispherectomy is performed in children whose seizures are associated with a disease that diffusely affects one cerebral hemisphere. (See  <a class="medical medical_review" href="/z/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features", section on 'Hemispheric syndromes'</a>.)</p><p>The most common causes of seizures in children undergoing hemispherectomy include encephalomalacia from a remote insult such as perinatal stroke, hemimegalencephaly, multilobar cortical dysplasia, Rasmussen encephalitis, and Sturge-Weber syndrome.</p><p>Seizure control rates after hemispherectomy are generally favorable across a range of etiologies, with approximately two-thirds of patients achieving seizure freedom at five years [<a href="#rid46">46-53</a>]. Predictors of worse seizure outcomes in most but not all studies include hemimegalencephaly [<a href="#rid46">46,51,54,55</a>], bilateral fluorodeoxyglucose (FDG)-PET abnormalities [<a href="#rid50">50</a>], bilateral MRI abnormalities [<a href="#rid54">54</a>], longer duration of epilepsy preceding surgery [<a href="#rid47">47,56</a>], and early postoperative seizure [<a href="#rid45">45,50</a>]. Of these, duration of epilepsy prior to surgery is the most consistently reported and underscores the importance of early surgical evaluation in patients with refractory seizures.</p><p>Contralateral MRI abnormalities are a common cause for concern in selecting patients for hemispherectomy, but their importance is controversial. This is demonstrated by two studies with conflicting results:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective series of 110 patients who underwent hemispherectomy, 74 percent of cases had contralateral MRI abnormalities, the majority of which were described as mild to moderate, including nonspecific white matter changes [<a href="#rid55">55</a>]. At a median follow-up of two years, rates of seizure freedom were similar in those with and without contralateral MRI abnormalities (79 and 83 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A smaller study of 43 patients found contralateral MRI abnormalities (described as "unambiguous" findings on visual inspection) in 26 percent of patients who underwent hemispherectomy [<a href="#rid54">54</a>]. After a median follow-up of seven years, patients with contralateral MRI abnormalities had lower rates of seizure freedom (45 versus 88 percent).</p><p></p><p>The definition of a contralateral MRI abnormality has varied across studies, and this may partly explain the discrepancy in results. In addition, the length of follow-up often differs, and those studies with shorter follow-up times might overestimate seizure control rates in one or both groups.</p><p>Other imaging modalities may also be helpful in selecting patients who will optimally benefit from surgery. In the largest study to date, FDG-PET activity in the contralateral hemisphere was a stronger predictor of seizure control postoperatively than MRI abnormalities; seizure freedom was achieved in 72 percent of the 119 patients with unilateral PET abnormalities and only 44 percent of the 18 patients with bilateral abnormalities [<a href="#rid50">50</a>].</p><p>Motor and cognitive outcomes after hemispherectomy are not as well studied as seizure outcomes. Most patients already have moderate to severe hemiparesis prior to undergoing hemispherectomy. The risk of added motor deficits is approximately 25 percent in the immediate postoperative period; most children regain function to their preoperative baseline or better by one year [<a href="#rid32">32</a>].</p><p>Postsurgical developmental gains reported in most studies are modest, but development is often limited by severe preexisting brain damage that may involve the nonoperated hemisphere [<a href="#rid49">49,54,56</a>]. As with seizure control, the most consistent predictor of cognitive and motor outcomes is shorter duration of epilepsy preceding surgery [<a href="#rid48">48,49,57,58</a>]. In addition, patients with fixed acquired etiologies (eg, perinatal stroke) tend to have better motor and cognitive outcomes than those with progressive or congenital etiologies.</p><p class="headingAnchor" id="H1539303050"><span class="h3">Corpus callosotomy</span><span class="headingEndMark"> — </span>In a corpus callosotomy, the fibers of the corpus callosum are surgically divided. Typically, an anterior two-thirds callosotomy is performed first, with completion of the callosotomy done only if seizures persist after the first procedure [<a href="#rid59">59</a>]. Selective posterior callosotomy has also been explored [<a href="#rid60">60</a>].</p><p>Corpus callosotomy is primarily considered in patients with atonic seizures, which are most commonly seen in epileptic encephalopathies such as Lennox-Gastaut syndrome [<a href="#rid61">61</a>]. However, other reports suggest that a substantive reduction in generalized tonic-clonic seizures and other seizure types can result after corpus callosotomy, and that improvements in behavior, intelligence quotient (IQ), and overall quality of life are also possible [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H72709230"><span class="h3">Others</span><span class="headingEndMark"> — </span>Stereotactic radiosurgery may be helpful for selected cases when the lesion is located where a conventional surgical approach is technically difficult or excessively risky [<a href="#rid63">63</a>]. More information is needed on long-term outcome before wider application of this procedure.</p><p class="headingAnchor" id="H1539303096"><span class="h2">Psychosocial outcomes</span><span class="headingEndMark"> — </span>The outcome of epilepsy surgery is typically measured by the degree of seizure control. Nonseizure outcomes, including psychosocial function and developmental outcomes, are less well-studied.</p><p>The available short-term data suggest that psychosocial outcomes at one year after epilepsy surgery are equivalent or better compared with ongoing medical therapy, especially among children with excellent postoperative seizure control [<a href="#rid23">23,32,64-66</a>]. Several observational studies with longer-term follow-up have suggested that IQ and other aspects of cognitive and psychosocial function improve over time compared with nonsurgical control patients, particularly in those patients who achieve seizure freedom or a reduction in antiseizure medications [<a href="#rid23">23,67-70</a>].</p><p class="headingAnchor" id="H1539304595"><span class="h2">Antiseizure medication management after surgery</span><span class="headingEndMark"> — </span>In some cases, epilepsy surgery affects a "cure," such that the patient is seizure-free off medication, but the risk for future seizure does not revert fully back to general population levels. Although seizure-free rates following temporal lobectomy may be as high as 70 to 80 percent, the longer patients are followed, the smaller this percentage becomes. A large study that examined seizure-free rates in over 600 adults 10 years after epilepsy surgery showed that only approximately 50 percent were still seizure-free [<a href="#rid71">71</a>]. Many patients therefore choose to remain on antiseizure medication following successful epilepsy surgery given their higher risk for seizure recurrence should they stop.</p><p>Observational studies on medication discontinuation after epilepsy surgery in children include the following series:</p><p class="bulletIndent1"><span class="glyph">●</span>The retrospective TimeToStop cohort study included 766 children who underwent epilepsy surgery over a seven-year period at one of 15 epilepsy centers across Europe and who began antiseizure medication reduction within a year of surgery [<a href="#rid72">72</a>]. The median times to antiseizure medication reduction and complete withdrawal were 13 and 29 months, respectively. Although earlier antiseizure medication withdrawal was associated with a higher risk for seizure recurrence, it did not affect long-term rates of seizure control or seizure freedom. This suggests that early antiseizure medication withdrawal may unmask incomplete surgical success sooner, identifying children who need ongoing antiseizure medication treatment and potentially sparing unnecessary continuation of antiseizure medications in others.</p><p></p><p class="bulletIndent1">In a separate study that included 301 children from this cohort for whom preoperative and postoperative IQ measurements were available, antiseizure medication reduction was associated with improved postoperative IQ scores, independent of other variables [<a href="#rid73">73</a>]. The largest gains were achieved in those who were able to completely discontinue antiseizure medications (mean gain of 5.6 points).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one survey of 140 children, 102 had completely discontinued medication, and 90 percent were seizure-free off medication [<a href="#rid74">74</a>]. Among those whose seizures recurred, seven were able to regain seizure control with restarting medication, and three had recurring seizures that were not controlled by restarting medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another cohort of 80 children, 44 percent relapsed without medication [<a href="#rid75">75</a>]. Relapse rates were somewhat lower, 32 percent, in children with temporal lobe resection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 97 children undergoing temporal lobectomy, neocortical resection, or multilobar surgery, medication was discontinued in 68 and 57 remained seizure-free for two or more years [<a href="#rid76">76</a>]. Only 5 of the 97 patients continued to have seizures on medications.</p><p></p><p>Many centers recommend continuing medication for at least six months following surgery. If the child is seizure-free, then each medication is slowly tapered, one at a time, starting with the one that seemed least effective prior to surgery or the one thought to be causing the most adverse effects. Even if the child is not completely seizure-free, an attempt should be made to minimize the number of medications, hopefully to monotherapy.</p><p class="headingAnchor" id="H2595342172"><span class="h1">NEUROSTIMULATION</span><span class="headingEndMark"> — </span>Neurostimulation techniques may be options for children with drug-resistant epilepsy who are not considered candidates for focal resective epilepsy surgery.</p><p class="headingAnchor" id="H1539303228"><span class="h2">Vagus nerve stimulation</span><span class="headingEndMark"> — </span>Many children who fail antiseizure medications therapy and the ketogenic diet are not candidates for resective epilepsy surgery. Others may undergo resective surgery and still have seizures. Others may have seizures controlled but with significant, bothersome side effects. These patients may be candidates for vagus nerve stimulation (VNS). VNS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2229.html" rel="external">"Vagus nerve stimulation therapy for the treatment of epilepsy"</a>.)</p><p class="headingAnchor" id="H4175901080"><span class="h2">Responsive neurostimulation</span><span class="headingEndMark"> — </span>Responsive neurostimulation (RNS) involves a closed-loop intracranial stimulation unit coupled with a seizure-detection system. Observational data suggest benefit for some children, but rigorous trials are lacking. In a report that identified 55 children from a pediatric epilepsy registry with drug-resistant epilepsy who were treated with RNS and followed for a mean of 11.7 months, four patients became seizure free with RNS off. Among 51 patients with stimulation data, the proportion of responders (those with a 50 percent or greater reduction in seizure frequency) was 65 percent, including 10 percent who were seizure free [<a href="#rid77">77</a>]. Complications, including transient weakness or malpositioned electrodes, occurred in 5 percent. An earlier systematic review identified 46 children treated with RNS and followed for a median of 22 months; the proportion of responders was 73 percent [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H3218612834"><span class="h2">Deep brain stimulation</span><span class="headingEndMark"> — </span>Subcortical deep brain stimulation (DBS) paradigms in adults have targeted the anterior and centromedian thalamic nuclei, the subthalamic nucleus, the caudate, hippocampus, and the cerebellum. Like RNS, observational data for children suggest benefit, but high-quality pediatric trials are lacking. A 2021 systematic review identified 72 children with drug-resistant epilepsy treated with DBS [<a href="#rid78">78</a>]. At a median follow-up of 14 months, the proportion with a 50 percent or more reduction in seizure frequency was 75 percent. Potential complications of DBS include implant site infection, hemorrhage, and pain; lead migration or misplacement; and cognitive and/or behavioral adverse effects [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H1539303287"><span class="h1">THE KETOGENIC DIET</span><span class="headingEndMark"> — </span>The ketogenic diet and related dietary modifications can be an effective treatment for patients with medically refractory epilepsy. This treatment, its indications, and potential adverse effects are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a>.)</p><p class="headingAnchor" id="H1539303351"><span class="h1">IMMUNOTHERAPIES</span><span class="headingEndMark"> — </span>Some epileptic syndromes (eg, Rasmussen encephalitis and others) may have an immunopathogenesis and as such may be responsive to immunotherapies, such as intravenous immunoglobulin and corticosteroids. Observational data are limited and inconsistent for these therapies in syndromes such as Rasmussen encephalitis, Landau-Kleffner syndrome, and electrical status epilepticus in sleep [<a href="#rid80">80-88</a>]. Further controlled studies are needed in order to define which syndromes benefit from such treatment. In general, use of such therapies is restricted to the care of children with intractable epilepsy followed in tertiary-care, subspecialty epilepsy clinics. (See  <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">"Epilepsy syndromes in children", section on 'Developmental and epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS)'</a>.)</p><p>The use of corticosteroid therapy in the treatment of infantile spasms and West syndrome is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6186.html" rel="external">"Infantile epileptic spasms syndrome: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H3194330401"><span class="h1">CANNABINOIDS</span><span class="headingEndMark"> — </span>Safety and efficacy data are accumulating for <a class="drug drug_pediatric" data-topicid="118392" href="/z/d/drug information/118392.html" rel="external">cannabidiol (pharmaceutical)</a>, a component of cannabis (marijuana) most commonly investigated in medical studies [<a href="#rid89">89-91</a>]. Several randomized trials have demonstrated modest efficacy of a standardized preparation of cannabidiol oil for patients with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), and cannabidiol (pharmaceutical) is approved by the FDA for the treatment of seizures associated with DS or LGS in patients ≥1 years of age. These data are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis", section on 'Cannabidiol'</a>.)</p><p>However, for other indications, cannabidiol or other cannabis compounds should not be used outside of the context of a clinical trial. Similarly, self-treatment with smoked marijuana is not recommended [<a href="#rid92">92</a>].</p><p>Adverse effects of cannabidiol include diarrhea, fatigue, drowsiness, and changes in appetite [<a href="#rid89">89-91</a>].</p><p>Cannabidiol is a potent inhibitor of the CYP3A and CYP2C enzymes [<a href="#rid93">93,94</a>], which are responsible for metabolism of <a class="drug drug_pediatric" data-topicid="83321" href="/z/d/drug information/83321.html" rel="external">clobazam</a> and many other antiseizure medications, including <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a>, <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">carbamazepine</a>, <a class="drug drug_pediatric" data-topicid="12841" href="/z/d/drug information/12841.html" rel="external">tiagabine</a>, and <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproate</a>  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 3</a>). In an open-label, prospective study of oral cannabidiol for drug-resistant epilepsy. a post hoc analysis found that patients on clobazam had a significantly higher responder rate (ie, a ≥50 percent reduction in motor seizures) compared with patients not taking clobazam (51 versus 27 percent) [<a href="#rid95">95</a>]. While metabolite levels were not followed in this study, a separate study found that clobazam metabolite levels rose by 60 percent with concomitant cannabidiol [<a href="#rid96">96</a>]. These effects may partially explain both toxicity and efficacy of cannabidiol in patients taking concurrent clobazam.</p><p>Importantly, long-term safety of cannabidiol has not been established, and significant concerns exist regarding the potential negative effects of chronic cannabis use on brain development, cognitive function, and school performance [<a href="#rid97">97,98</a>], particularly in children with drug-resistant epilepsy, who may have increased vulnerability to such effects.</p><p>Patients receiving cannabinoids should be monitored for adverse effects, including elevated liver function tests. Given the potential for drug-drug interactions with other antiseizure medications, closer serum monitoring of antiseizure medication levels may be prudent [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H1703126316"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">"Society guideline links: Seizures and epilepsy in children"</a>.)</p><p class="headingAnchor" id="H1539304689"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>When seizures do not respond as expected to initial antiseizure medication therapy, it is important to reconsider the seizure classification and the appropriateness of the antiseizure medication regimens that have been tried. In addition, clinicians should consider whether the diagnosis of epilepsy is accurate, as misdiagnosis is common. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The first antiseizure medication fails in 20 to 40 percent of children with epilepsy; lack of efficacy and side effects contribute roughly equally to treatment failure. Adding a second antiseizure medication is a reasonable next step when seizures are resistant to adequate doses of the initial drug. For children on polytherapy who continue to have inadequate seizure control, seizure frequency is sometimes improved when the number of antiseizure medications is reduced. (See <a class="local">'Adding a second antiseizure medication'</a> above and <a class="local">'Inadequate response to multidrug therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transmucosal antiseizure medication administration (eg, rectal <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a>) is an effective and relatively safe emergency treatment for patients with prolonged seizures or seizure clusters in settings where intravenous access is not readily available. (See <a class="local">'Home rescue therapy (transmucosal antiseizure medications)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When a child has intractable epilepsy despite treatment with more than one antiseizure medication, referral to a comprehensive epilepsy center is appropriate to determine eligibility for epilepsy surgery and other treatment modalities, such as dietary therapy and vagus nerve stimulation (VNS).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A number of effective surgical treatments are available (focal resections, lobar or multilobar resections, corpus callosotomy, hemispherectomy, and multiple subpial transection). The procedure selected depends upon the type and localization of the seizures. (See <a class="local">'Epilepsy surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The ketogenic diet can be an effective treatment for specific patients with medically refractory epilepsy. This treatment, its indications, and potential adverse effects are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VNS is also effective in the treatment of refractory epilepsy when surgery is not an option. (See  <a class="medical medical_review" href="/z/d/html/2229.html" rel="external">"Vagus nerve stimulation therapy for the treatment of epilepsy"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51:1069.</a></li><li><a class="nounderline abstract_t">Dudley RW, Penney SJ, Buckley DJ. First-drug treatment failures in children newly diagnosed with epilepsy. Pediatr Neurol 2009; 40:71.</a></li><li><a class="nounderline abstract_t">Sloan ME, Simard-Tremblay E, Shevell MI. Features of a subset of children with complex partial epilepsy requiring combination therapy for effective seizure control. J Child Neurol 2010; 25:43.</a></li><li><a class="nounderline abstract_t">Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39:5.</a></li><li><a class="nounderline abstract_t">Labiner DM, Bagic AI, Herman ST, et al. Essential services, personnel, and facilities in specialized epilepsy centers--revised 2010 guidelines. Epilepsia 2010; 51:2322.</a></li><li><a class="nounderline abstract_t">McKee HR, Abou-Khalil B. Outpatient pharmacotherapy and modes of administration for acute repetitive and prolonged seizures. CNS Drugs 2015; 29:55.</a></li><li><a class="nounderline abstract_t">Wiznitzer M. Buccal midazolam for seizures. Lancet 2005; 366:182.</a></li><li><a class="nounderline abstract_t">McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med 2010; 17:575.</a></li><li><a class="nounderline abstract_t">Pellock JM, Shinnar S. Respiratory adverse events associated with diazepam rectal gel. Neurology 2005; 64:1768.</a></li><li><a class="nounderline abstract_t">Rowland AG, Gill AM, Stewart AB, et al. Review of the efficacy of rectal paraldehyde in the management of acute and prolonged tonic-clonic convulsions. Arch Dis Child 2009; 94:720.</a></li><li><a class="nounderline abstract_t">Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353:623.</a></li><li><a class="nounderline abstract_t">McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 366:205.</a></li><li><a class="nounderline abstract_t">Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev 2009; 31:744.</a></li><li class="breakAll">Prescribing information Valtoco (diazepam nasal spray). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211635s000lbl.pdf (Accessed on January 15, 2020).</li><li class="breakAll">Prescribing information Nayzilam (midazolam) nasal spray. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf (Accessed on January 15, 2020).</li><li><a class="nounderline abstract_t">Chhabra R, Gupta R, Gupta LK. Intranasal midazolam versus intravenous/rectal benzodiazepines for acute seizure control in children: A systematic review and meta-analysis. Epilepsy Behav 2021; 125:108390.</a></li><li><a class="nounderline abstract_t">Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. Lancet 2006; 367:1591.</a></li><li><a class="nounderline abstract_t">Arya R, Gulati S, Kabra M, et al. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia 2011; 52:788.</a></li><li><a class="nounderline abstract_t">Wait S, Lagae L, Arzimanoglou A, et al. The administration of rescue medication to children with prolonged acute convulsive seizures in the community: what happens in practice? Eur J Paediatr Neurol 2013; 17:14.</a></li><li><a class="nounderline abstract_t">Cross JH, Wait S, Arzimanoglou A, et al. Are we failing to provide adequate rescue medication to children at risk of prolonged convulsive seizures in schools? Arch Dis Child 2013; 98:777.</a></li><li><a class="nounderline abstract_t">Hartman AL, Devore CD, Section on Neurology, American Academy of Pediatrics, et al. Rescue Medicine for Epilepsy in Education Settings. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Steinbok P, Gan PY, Connolly MB, et al. Epilepsy surgery in the first 3 years of life: a Canadian survey. Epilepsia 2009; 50:1442.</a></li><li><a class="nounderline abstract_t">Roulet-Perez E, Davidoff V, Mayor-Dubois C, et al. Impact of severe epilepsy on development: recovery potential after successful early epilepsy surgery. Epilepsia 2010; 51:1266.</a></li><li><a class="nounderline abstract_t">Oguni H, Olivier A, Andermann F, Comair J. Anterior callosotomy in the treatment of medically intractable epilepsies: a study of 43 patients with a mean follow-up of 39 months. Ann Neurol 1991; 30:357.</a></li><li><a class="nounderline abstract_t">Morrell F, Whisler WW, Smith MC, et al. Landau-Kleffner syndrome. Treatment with subpial intracortical transection. Brain 1995; 118 ( Pt 6):1529.</a></li><li><a class="nounderline abstract_t">Vigevano F, Bertini E, Boldrini R, et al. Hemimegalencephaly and intractable epilepsy: benefits of hemispherectomy. Epilepsia 1989; 30:833.</a></li><li><a class="nounderline abstract_t">Vining EP, Freeman JM, Pillas DJ, et al. Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996. Pediatrics 1997; 100:163.</a></li><li><a class="nounderline abstract_t">Vining EP, Freeman JM, Brandt J, et al. Progressive unilateral encephalopathy of childhood (Rasmussen's syndrome): a reappraisal. Epilepsia 1993; 34:639.</a></li><li><a class="nounderline abstract_t">Leach JP, Chadwick DW, Miles JB, Hart IK. Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Neurology 1999; 52:738.</a></li><li><a class="nounderline abstract_t">Cossu M, Pelliccia V, Gozzo F, et al. Surgical treatment of polymicrogyria-related epilepsy. Epilepsia 2016; 57:2001.</a></li><li><a class="nounderline abstract_t">Maillard LG, Tassi L, Bartolomei F, et al. Stereoelectroencephalography and surgical outcome in polymicrogyria-related epilepsy: A multicentric study. Ann Neurol 2017; 82:781.</a></li><li><a class="nounderline abstract_t">Dwivedi R, Ramanujam B, Chandra PS, et al. Surgery for Drug-Resistant Epilepsy in Children. N Engl J Med 2017; 377:1639.</a></li><li><a class="nounderline abstract_t">Widjaja E, Jain P, Demoe L, et al. Seizure outcome of pediatric epilepsy surgery: Systematic review and meta-analyses. Neurology 2020; 94:311.</a></li><li><a class="nounderline abstract_t">Wiebe S, Blume WT, Girvin JP, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345:311.</a></li><li><a class="nounderline abstract_t">Blumcke I, Spreafico R, Haaker G, et al. Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. N Engl J Med 2017; 377:1648.</a></li><li><a class="nounderline abstract_t">Maton B, Jayakar P, Resnick T, et al. Surgery for medically intractable temporal lobe epilepsy during early life. Epilepsia 2008; 49:80.</a></li><li><a class="nounderline abstract_t">Mizrahi EM, Kellaway P, Grossman RG, et al. Anterior temporal lobectomy and medically refractory temporal lobe epilepsy of childhood. Epilepsia 1990; 31:302.</a></li><li><a class="nounderline abstract_t">Wyllie E, Comair YG, Kotagal P, et al. Seizure outcome after epilepsy surgery in children and adolescents. Ann Neurol 1998; 44:740.</a></li><li><a class="nounderline abstract_t">Cossu M, Lo Russo G, Francione S, et al. Epilepsy surgery in children: results and predictors of outcome on seizures. Epilepsia 2008; 49:65.</a></li><li><a class="nounderline abstract_t">Wyllie E, Lachhwani DK, Gupta A, et al. Successful surgery for epilepsy due to early brain lesions despite generalized EEG findings. Neurology 2007; 69:389.</a></li><li><a class="nounderline abstract_t">Duchowny M, Jayakar P, Resnick T, et al. Epilepsy surgery in the first three years of life. Epilepsia 1998; 39:737.</a></li><li><a class="nounderline abstract_t">Ko A, Kim SH, Kim SH, et al. Epilepsy Surgery for Children With Low-Grade Epilepsy-Associated Tumors: Factors Associated With Seizure Recurrence and Cognitive Function. Pediatr Neurol 2019; 91:50.</a></li><li><a class="nounderline abstract_t">Fish DR, Smith SJ, Quesney LF, et al. Surgical treatment of children with medically intractable frontal or temporal lobe epilepsy: results and highlights of 40 years' experience. Epilepsia 1993; 34:244.</a></li><li><a class="nounderline abstract_t">Jayakar P, Dunoyer C, Dean P, et al. Epilepsy surgery in patients with normal or nonfocal MRI scans: integrative strategies offer long-term seizure relief. Epilepsia 2008; 49:758.</a></li><li><a class="nounderline abstract_t">Mani J, Gupta A, Mascha E, et al. Postoperative seizures after extratemporal resections and hemispherectomy in pediatric epilepsy. Neurology 2006; 66:1038.</a></li><li><a class="nounderline abstract_t">Jonas R, Nguyen S, Hu B, et al. Cerebral hemispherectomy: hospital course, seizure, developmental, language, and motor outcomes. Neurology 2004; 62:1712.</a></li><li><a class="nounderline abstract_t">Cukiert A, Cukiert CM, Argentoni M, et al. Outcome after hemispherectomy in hemiplegic adult patients with refractory epilepsy associated with early middle cerebral artery infarcts. Epilepsia 2009; 50:1381.</a></li><li><a class="nounderline abstract_t">Devlin AM, Cross JH, Harkness W, et al. Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence. Brain 2003; 126:556.</a></li><li><a class="nounderline abstract_t">Basheer SN, Connolly MB, Lautzenhiser A, et al. Hemispheric surgery in children with refractory epilepsy: seizure outcome, complications, and adaptive function. Epilepsia 2007; 48:133.</a></li><li><a class="nounderline abstract_t">Moosa AN, Gupta A, Jehi L, et al. Longitudinal seizure outcome and prognostic predictors after hemispherectomy in 170 children. Neurology 2013; 80:253.</a></li><li><a class="nounderline abstract_t">Delalande O, Bulteau C, Dellatolas G, et al. Vertical parasagittal hemispherotomy: surgical procedures and clinical long-term outcomes in a population of 83 children. Neurosurgery 2007; 60:ONS19.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Vining EP, Pillas DJ, et al. Hemispherectomy for intractable unihemispheric epilepsy etiology vs outcome. Neurology 2003; 61:887.</a></li><li><a class="nounderline abstract_t">Schramm J, Kuczaty S, Sassen R, et al. Pediatric functional hemispherectomy: outcome in 92 patients. Acta Neurochir (Wien) 2012; 154:2017.</a></li><li><a class="nounderline abstract_t">Boshuisen K, van Schooneveld MM, Leijten FS, et al. Contralateral MRI abnormalities affect seizure and cognitive outcome after hemispherectomy. Neurology 2010; 75:1623.</a></li><li><a class="nounderline abstract_t">Hallbook T, Ruggieri P, Adina C, et al. Contralateral MRI abnormalities in candidates for hemispherectomy for refractory epilepsy. Epilepsia 2010; 51:556.</a></li><li><a class="nounderline abstract_t">Duchowny M. Hemispherectomy for epilepsy: when is one half better than two? Neurology 2004; 62:1664.</a></li><li><a class="nounderline abstract_t">Samargia SA, Kimberley TJ. Motor and cognitive outcomes in children after functional hemispherectomy. Pediatr Phys Ther 2009; 21:356.</a></li><li><a class="nounderline abstract_t">Honda R, Kaido T, Sugai K, et al. Long-term developmental outcome after early hemispherotomy for hemimegalencephaly in infants with epileptic encephalopathy. Epilepsy Behav 2013; 29:30.</a></li><li><a class="nounderline abstract_t">Graham D, Tisdall MM, Gill D. Corpus callosotomy outcomes in pediatric patients: A systematic review. Epilepsia 2016; 57:1053.</a></li><li><a class="nounderline abstract_t">Paglioli E, Martins WA, Azambuja N, et al. Selective posterior callosotomy for drop attacks: A new approach sparing prefrontal connectivity. Neurology 2016; 87:1968.</a></li><li><a class="nounderline abstract_t">Asadi-Pooya AA, Sharan A, Nei M, Sperling MR. Corpus callosotomy. Epilepsy Behav 2008; 13:271.</a></li><li><a class="nounderline abstract_t">Cukiert A, Burattini JA, Mariani PP, et al. Outcome after extended callosal section in patients with primary idiopathic generalized epilepsy. Epilepsia 2009; 50:1377.</a></li><li><a class="nounderline abstract_t">Dunoyer C, Ragheb J, Resnick T, et al. The use of stereotactic radiosurgery to treat intractable childhood partial epilepsy. Epilepsia 2002; 43:292.</a></li><li><a class="nounderline abstract_t">Smith ML, Elliott IM, Lach L. Cognitive, psychosocial, and family function one year after pediatric epilepsy surgery. Epilepsia 2004; 45:650.</a></li><li><a class="nounderline abstract_t">Sabaz M, Lawson JA, Cairns DR, et al. The impact of epilepsy surgery on quality of life in children. Neurology 2006; 66:557.</a></li><li><a class="nounderline abstract_t">Gleissner U, Clusmann H, Sassen R, et al. Postsurgical outcome in pediatric patients with epilepsy: a comparison of patients with intellectual disabilities, subaverage intelligence, and average-range intelligence. Epilepsia 2006; 47:406.</a></li><li><a class="nounderline abstract_t">Elliott IM, Lach L, Kadis DS, Smith ML. Psychosocial outcomes in children two years after epilepsy surgery: has anything changed? Epilepsia 2008; 49:634.</a></li><li><a class="nounderline abstract_t">Skirrow C, Cross JH, Cormack F, et al. Long-term intellectual outcome after temporal lobe surgery in childhood. Neurology 2011; 76:1330.</a></li><li><a class="nounderline abstract_t">Viggedal G, Kristjansdottir R, Olsson I, et al. Cognitive development from two to ten years after pediatric epilepsy surgery. Epilepsy Behav 2012; 25:2.</a></li><li><a class="nounderline abstract_t">Sibilia V, Barba C, Metitieri T, et al. Cognitive outcome after epilepsy surgery in children: A controlled longitudinal study. Epilepsy Behav 2017; 73:23.</a></li><li><a class="nounderline abstract_t">de Tisi J, Bell GS, Peacock JL, et al. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet 2011; 378:1388.</a></li><li><a class="nounderline abstract_t">Boshuisen K, Arzimanoglou A, Cross JH, et al. Timing of antiepileptic drug withdrawal and long-term seizure outcome after paediatric epilepsy surgery (TimeToStop): a retrospective observational study. Lancet Neurol 2012; 11:784.</a></li><li><a class="nounderline abstract_t">Boshuisen K, van Schooneveld MM, Uiterwaal CS, et al. Intelligence quotient improves after antiepileptic drug withdrawal following pediatric epilepsy surgery. Ann Neurol 2015; 78:104.</a></li><li><a class="nounderline abstract_t">Hoppe C, Poepel A, Sassen R, Elger CE. Discontinuation of anticonvulsant medication after epilepsy surgery in children. Epilepsia 2006; 47:580.</a></li><li><a class="nounderline abstract_t">Sinclair DB, Jurasek L, Wheatley M, et al. Discontinuation of antiepileptic drugs after pediatric epilepsy surgery. Pediatr Neurol 2007; 37:200.</a></li><li><a class="nounderline abstract_t">Lachhwani DK, Loddenkemper T, Holland KD, et al. Discontinuation of medications after successful epilepsy surgery in children. Pediatr Neurol 2008; 38:340.</a></li><li><a class="nounderline abstract_t">Singh RK, Eschbach K, Samanta D, et al. Responsive Neurostimulation in Drug-Resistant Pediatric Epilepsy: Findings From the Epilepsy Surgery Subgroup of the Pediatric Epilepsy Research Consortium. Pediatr Neurol 2023; 143:106.</a></li><li><a class="nounderline abstract_t">Khan M, Paktiawal J, Piper RJ, et al. Intracranial neuromodulation with deep brain stimulation and responsive neurostimulation in children with drug-resistant epilepsy: a systematic review. J Neurosurg Pediatr 2021; :1.</a></li><li><a class="nounderline abstract_t">DiFrancesco MF, Halpern CH, Hurtig HH, et al. Pediatric indications for deep brain stimulation. Childs Nerv Syst 2012; 28:1701.</a></li><li><a class="nounderline abstract_t">Geva-Dayan K, Shorer Z, Menascu S, et al. Immunoglobulin treatment for severe childhood epilepsy. Pediatr Neurol 2012; 46:375.</a></li><li><a class="nounderline abstract_t">Billiau AD, Witters P, Ceulemans B, et al. Intravenous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile. Epilepsia 2007; 48:1739.</a></li><li><a class="nounderline abstract_t">Mikati MA, Kurdi R, El-Khoury Z, et al. Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature. Epilepsy Behav 2010; 17:90.</a></li><li><a class="nounderline abstract_t">Geng J, Dong J, Li Y, et al. Intravenous immunoglobulins for epilepsy. Cochrane Database Syst Rev 2011; :CD008557.</a></li><li><a class="nounderline abstract_t">Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69:582.</a></li><li><a class="nounderline abstract_t">Wong-Kisiel LC, McKeon A, Wirrell EC. Autoimmune encephalopathies and epilepsies in children and teenagers. Can J Neurol Sci 2012; 39:134.</a></li><li><a class="nounderline abstract_t">Varadkar S, Bien CG, Kruse CA, et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol 2014; 13:195.</a></li><li><a class="nounderline abstract_t">Lagarde S, Villeneuve N, Trébuchon A, et al. Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: An open pilot study. Epilepsia 2016; 57:956.</a></li><li><a class="nounderline abstract_t">Jaafar F, Obeid M, Beydoun A. Role of Early Intravenous Immunoglobulins in Halting Clinical and Radiographic Disease Progression in Rasmussen Encephalitis. Pediatr Neurol 2023; 145:30.</a></li><li><a class="nounderline abstract_t">Samanta D. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Pediatr Neurol 2019; 96:24.</a></li><li><a class="nounderline abstract_t">Elliott J, DeJean D, Clifford T, et al. Cannabis-based products for pediatric epilepsy: A systematic review. Epilepsia 2019; 60:6.</a></li><li><a class="nounderline abstract_t">Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018; 89:741.</a></li><li><a class="nounderline abstract_t">Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82:1556.</a></li><li><a class="nounderline abstract_t">Watanabe K, Yamaori S, Funahashi T, et al. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007; 80:1415.</a></li><li><a class="nounderline abstract_t">Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 2011; 88:730.</a></li><li><a class="nounderline abstract_t">Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016; 15:270.</a></li><li><a class="nounderline abstract_t">Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015; 56:1246.</a></li><li><a class="nounderline abstract_t">Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014; 370:2219.</a></li><li><a class="nounderline abstract_t">Zalesky A, Solowij N, Yücel M, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012; 135:2245.</a></li><li><a class="nounderline abstract_t">Gaston TE, Bebin EM, Cutter GR, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia 2017; 58:1586.</a></li></ol></div><div id="topicVersionRevision">Topic 101361 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889013" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135617" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : First-drug treatment failures in children newly diagnosed with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494358" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Features of a subset of children with complex partial epilepsy requiring combination therapy for effective seizure control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578007" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiepileptic drugs as a cause of worsening seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20561026" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Essential services, personnel, and facilities in specialized epilepsy centers--revised 2010 guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583219" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outpatient pharmacotherapy and modes of administration for acute repetitive and prolonged seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16023491" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Buccal midazolam for seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20624136" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911807" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Respiratory adverse events associated with diazepam rectal gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357123" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Review of the efficacy of rectal paraldehyde in the management of acute and prolonged tonic-clonic convulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10030327" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16023510" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114297" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114297" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114297" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740090" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intranasal midazolam versus intravenous/rectal benzodiazepines for acute seizure control in children: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698412" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21275979" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22863944" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The administration of rescue medication to children with prolonged acute convulsive seizures in the community: what happens in practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899921" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Are we failing to provide adequate rescue medication to children at risk of prolonged convulsive seizures in schools?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26712862" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rescue Medicine for Epilepsy in Education Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19175388" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epilepsy surgery in the first 3 years of life: a Canadian survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132288" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Impact of severe epilepsy on development: recovery potential after successful early epilepsy surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1952824" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anterior callosotomy in the treatment of medically intractable epilepsies: a study of 43 patients with a mean follow-up of 39 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8595482" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Landau-Kleffner syndrome. Treatment with subpial intracortical transection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2591346" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hemimegalencephaly and intractable epilepsy: benefits of hemispherectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240794" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8330574" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Progressive unilateral encephalopathy of childhood (Rasmussen's syndrome): a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10078719" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27778326" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Surgical treatment of polymicrogyria-related epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29059488" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Stereoelectroencephalography and surgical outcome in polymicrogyria-related epilepsy: A multicentric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29069568" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Surgery for Drug-Resistant Epilepsy in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31996452" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Seizure outcome of pediatric epilepsy surgery: Systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11484687" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomized, controlled trial of surgery for temporal-lobe epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29069555" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868049" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Surgery for medically intractable temporal lobe epilepsy during early life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2344847" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Anterior temporal lobectomy and medically refractory temporal lobe epilepsy of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818929" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Seizure outcome after epilepsy surgery in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17645538" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Epilepsy surgery in children: results and predictors of outcome on seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646632" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Successful surgery for epilepsy due to early brain lesions despite generalized EEG findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9670902" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epilepsy surgery in the first three years of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30477743" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Epilepsy Surgery for Children With Low-Grade Epilepsy-Associated Tumors: Factors Associated With Seizure Recurrence and Cognitive Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8453932" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Surgical treatment of children with medically intractable frontal or temporal lobe epilepsy: results and highlights of 40 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18266748" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Epilepsy surgery in patients with normal or nonfocal MRI scans: integrative strategies offer long-term seizure relief.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606916" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Postoperative seizures after extratemporal resections and hemispherectomy in pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159467" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cerebral hemispherectomy: hospital course, seizure, developmental, language, and motor outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19183223" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Outcome after hemispherectomy in hemiplegic adult patients with refractory epilepsy associated with early middle cerebral artery infarcts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12566277" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241220" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hemispheric surgery in children with refractory epilepsy: seizure outcome, complications, and adaptive function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223541" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Longitudinal seizure outcome and prognostic predictors after hemispherectomy in 170 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17297362" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vertical parasagittal hemispherotomy: surgical procedures and clinical long-term outcomes in a population of 83 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557554" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hemispherectomy for intractable unihemispheric epilepsy etiology vs outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22941395" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pediatric functional hemispherectomy: outcome in 92 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21041785" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Contralateral MRI abnormalities affect seizure and cognitive outcome after hemispherectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19817811" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Contralateral MRI abnormalities in candidates for hemispherectomy for refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159458" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hemispherectomy for epilepsy: when is one half better than two?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19923976" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Motor and cognitive outcomes in children after functional hemispherectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23933627" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term developmental outcome after early hemispherotomy for hemimegalencephaly in infants with epileptic encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27237542" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Corpus callosotomy outcomes in pediatric patients: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27733569" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Selective posterior callosotomy for drop attacks: A new approach sparing prefrontal connectivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539083" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Corpus callosotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054399" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Outcome after extended callosal section in patients with primary idiopathic generalized epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11906515" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The use of stereotactic radiosurgery to treat intractable childhood partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15144430" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cognitive, psychosocial, and family function one year after pediatric epilepsy surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505311" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The impact of epilepsy surgery on quality of life in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499768" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Postsurgical outcome in pediatric patients with epilepsy: a comparison of patients with intellectual disabilities, subaverage intelligence, and average-range intelligence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18177356" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Psychosocial outcomes in children two years after epilepsy surgery: has anything changed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482948" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long-term intellectual outcome after temporal lobe surgery in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22980073" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cognitive development from two to ten years after pediatric epilepsy surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605630" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cognitive outcome after epilepsy surgery in children: A controlled longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000136" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22841352" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Timing of antiepileptic drug withdrawal and long-term seizure outcome after paediatric epilepsy surgery (TimeToStop): a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25899932" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intelligence quotient improves after antiepileptic drug withdrawal following pediatric epilepsy surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16529625" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Discontinuation of anticonvulsant medication after epilepsy surgery in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765808" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Discontinuation of antiepileptic drugs after pediatric epilepsy surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410850" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Discontinuation of medications after successful epilepsy surgery in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37084698" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Responsive Neurostimulation in Drug-Resistant Pediatric Epilepsy: Findings From the Epilepsy Surgery Subgroup of the Pediatric Epilepsy Research Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34678764" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Intracranial neuromodulation with deep brain stimulation and responsive neurostimulation in children with drug-resistant epilepsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22828866" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pediatric indications for deep brain stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633633" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Immunoglobulin treatment for severe childhood epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17521345" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Intravenous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004620" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21249713" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Intravenous immunoglobulins for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22451162" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Autoimmune epilepsy: clinical characteristics and response to immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343145" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Autoimmune encephalopathies and epilepsies in children and teenagers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24457189" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27106864" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: An open pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37269621" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Role of Early Intravenous Immunoglobulins in Halting Clinical and Radiographic Disease Progression in Rasmussen Encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31053391" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30515765" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cannabis-based products for pediatric epilepsy: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29511052" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24778283" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17303175" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21356216" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26724101" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26114620" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24897085" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Adverse health effects of marijuana use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22669080" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effect of long-term cannabis use on axonal fibre connectivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28782097" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Interactions between cannabidiol and commonly used antiepileptic drugs.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
